Canaccord Genuity is pleased to announce that on March 5, 2014, it completed an underwritten secondary public offering of ordinary shares for Enzymotec Ltd. (Nasdaq: ENZY). The company issued a total of 4,698,857 shares of stock (upsized from 4,000,000 shares) at a price of $28.00 per share. The over-allotment option granted by Enzymotec to the underwriters was fully exercised to purchase an additional 704,828 shares bringing the total the deal size to 5,403,685 shares or approximately $151 million. The selling shareholders will receive all net proceeds from the sale of shares in this offering. Canaccord Genuity Inc. acted as senior co-manager for the offering. 

Enzymotec Ltd. is a specialty lipids-based platform company dedicated to the research, development and commercialization of innovative bioactive products and ingredients for the nutritional supplements and pharmaceuticals markets. The Company develops, manufactures and markets innovative biofunctional ingredients and final products based on sophisticated proprietary technologies.